COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL. (12th June 2019) - Jain, P.; Romaguera, J.; Nomie, K.; Zhang, S.; Wang, L.; Oriabure, O.; Wagner‐Bartak, N.; Zhang, L.; Hagemeister, F.; Samaniego, F.; Westin, J.; Ju Lee, H.; et al.